Marco Astegiano

Plain English
This study looked at how different doctors manage irritable bowel syndrome (IBS), a common condition that can cause symptoms like diarrhea and constipation. It involved 2,442 patients and compared the approaches of 53 gastroenterologists and 42 general practitioners. Researchers found that gastroenterologists tended to handle more complicated cases and prescribed more appropriate tests, while general practitioners more often used food supplements. Importantly, using specific supplements called symbiotics led to less pain and discomfort for patients. Who this helps: This helps patients with IBS by improving their diagnosis and treatment options.

Plain English
This research examined how a combination of traditional Proton Pump Inhibitors (PPIs) and a new treatment called Nux vomica-Heel can be used to manage gastro-esophageal reflux disease (GERD), which affects about 20% of people in Western countries. A group of 49 Italian doctors reached a consensus that this combined approach could be beneficial, with agreement levels on treatment strategies ranging from 90% to 100%. This matters because PPIs can have negative side effects if used long-term, so finding safer alternatives like Nux vomica-Heel can help manage GERD effectively. Who this helps: Patients suffering from GERD who need safer treatment options.

Plain English
This study looked at how anemia affects people with inflammatory bowel disease (IBD) and found that 13.6% of those patients had anemia, primarily due to iron deficiency. Over 24 weeks, patients' hemoglobin levels improved from an average of 108 g/L to 121 g/L, especially when they received iron supplements, but the majority remained anemic throughout the study. Anemia significantly worsened patients' fatigue and quality of life, indicating it’s a persistent challenge for many with IBD. Who this helps: This helps patients with IBD who suffer from anemia and their doctors in managing their treatment.

Plain English
This study looked at how long it takes for adults in Italy to get diagnosed with coeliac disease (CD) and what causes delays. It found that, on average, patients waited 8 months to receive a diagnosis, with some factors like having a previous misdiagnosis leading to even longer delays. Specifically, those with neurological symptoms or a history of misdiagnosis experienced much longer wait times—up to 9.8 months more for some. Understanding these delays is important because better screening strategies could be developed to help patients receive timely diagnoses. Who this helps: This helps patients with coeliac disease and their doctors.

Plain English
This study looked at how common inflammatory bowel diseases (IBD), like Crohn's disease and ulcerative colitis, have become in a specific area of North-West Italy over time. Researchers found that the number of people with IBD rose from 200 per 100,000 in 2006 to 321.2 per 100,000 in 2021, marking a 46% increase. Additionally, the rate at which new cases are diagnosed jumped from 6.7 per 100,000 people per year to 18.0 per 100,000, an increase of 169%. These findings highlight the growing need for better care and resources for people with these conditions. Who this helps: Patients suffering from inflammatory bowel diseases.

Plain English
This study looked at how a gluten-free diet (GFD) affects certain small molecules and the bacteria in the gut of people with celiac disease. Researchers found that for individuals strictly following the GFD, specific markers in their stool showed less difference compared to healthy people the longer they were on the diet. This is important because it means tracking these markers could help doctors better manage celiac disease and see how well patients are doing with their diet. Who this helps: This helps patients with celiac disease and their doctors.

Plain English
This study looked at anemia in patients with inflammatory bowel disease (IBD) across 28 hospitals in Italy. Out of 5,416 patients, 737 (about 14%) were found to be anemic, predominantly due to iron deficiency. The research highlights that severe anemia worsens fatigue and quality of life, yet many patients—69% with iron deficiency and 35% with vitamin deficiencies—are not receiving the necessary treatment. Who this helps: This information benefits patients with IBD and their doctors by highlighting the importance of properly managing anemia.

Plain English
This study looked at how the small intestine works, specifically its ability to let certain substances in and the role of the microbes that live there. Researchers found that when the intestine becomes more porous, it can lead to increased interactions with the immune system, which might trigger diseases like coeliac disease, type 1 diabetes, and asthma. Understanding how the small intestine functions is important because it helps explain how various health issues, not just digestion-related ones, can develop. Who this helps: This research benefits patients with immune-related conditions and their doctors.

Plain English
This study looked at how the timing of surgery affects complications after surgery for Crohn's disease. It found that patients who waited longer to have their surgery faced a higher risk of major complications, with a 10% increase in risk for each additional year they waited. Complications included serious issues in 29 patients and leaking at the surgery site in 16 patients. This matters because it highlights the importance of timely surgery to minimize risks for patients with Crohn's disease. Who this helps: This helps patients with Crohn's disease who may need surgery.

Plain English
This study looked at patients with Crohn's disease who had surgery to see what factors might lead to the return of their symptoms after surgery. Out of 162 patients followed for about 11 years, 21.3% experienced a recurrence. Key risks for this included being 28 years or younger at surgery, smoking, being female, having certain abnormalities in lymph nodes, and using corticosteroids after surgery, while a specific tissue change (cryptitis) seemed to reduce the risk. Who this helps: This research helps doctors better manage treatment plans for Crohn's disease patients to reduce their chances of surgery-related issues.

Plain English
This study focused on a new oral treatment for nonerosive reflux disease (NERD), which causes symptoms like heartburn but doesn't damage the esophagus. Researchers found that 95% of patients taking the treatment reported significant symptom relief, compared to only 20% of those taking a placebo. This is important because it shows a strong potential treatment option for people who do not respond well to standard medications. Who this helps: This helps patients suffering from nonerosive reflux disease.

Plain English
This study looked at how liver transplants affect people with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). Researchers found that the need for advanced treatments or hospitalizations due to IBD was similar in both patients who had liver transplants (41% needed more treatment) and those who didn't (35% needed more treatment). However, patients who had liver transplants experienced higher rates of certain cancers, with significant increases in lymphoma and other tumors. Who this helps: This information helps doctors and patients understand the risks and complications of liver transplants in the context of IBD and PSC.

Plain English
This study looked at the effectiveness and safety of a medication called ABP 501, which is a biosimilar to adalimumab, in treating Crohn's disease. The researchers found that switching to ABP 501 was effective and safe for patients, allowing for better allocation of healthcare resources. This matters because it shows that patients can access affordable treatment options without compromising their care. Who this helps: This helps patients with Crohn's disease looking for effective and cost-efficient treatment options.

Plain English
This study looked at people who think they have a sensitivity to gluten or wheat but do not have celiac disease. Out of 50 participants, 27 (54%) had real gluten sensitivity, while 23 responded to a placebo, indicating that many symptoms might not be related to gluten. Those with true sensitivity had better mental health scores and a lower risk of eating disorders compared to those who reacted to the placebo. Who this helps: This benefits patients with suspected gluten sensitivity and their healthcare providers.

Plain English
This study looked at the risk of urothelial cancer, a type of bladder cancer, in patients with inflammatory bowel disease (IBD). Researchers analyzed the medical records of over 5,700 IBD patients from 1978 to 2021 and found that 24 of them had urothelial cancer, which is about 0.42%, the same as in the general population. They also identified that smoking and being male significantly increase the risk of developing this cancer for those with IBD. Who this helps: This research is beneficial for patients with IBD, especially those who smoke or are male, as it highlights their increased risk of urothelial cancer.

Plain English
This study looked at how patients with Crohn's disease react when switching from one biosimilar version of adalimumab (a drug used to treat the condition) to another. The researchers followed 61 patients and found that 88.5% continued to successfully use the new biosimilar after 6 months, and 82% did not need to increase their dose or use additional steroids. Only a few patients experienced side effects, which were similar to what was seen before switching. Who this helps: This research benefits patients with Crohn's disease who are considering switching biosimilar medications.

Plain English
This study looked at how a type of medication called TNF inhibitors, used to treat inflammatory bowel diseases (IBD) and related arthritis, affects gut bacteria in patients. After six months of treatment, there was a significant increase in beneficial gut bacteria from the Lachnospiraceae family (up by 10.3) and Coprococcus genus (up by 2.8). This matters because a healthier balance of gut bacteria can improve overall wellbeing and manage inflammation linked to these conditions. Who this helps: Patients with IBD-related spondyloarthritis.

Plain English
This study looked at whether a combination of calcium butyrate and fructooligosaccharides could help prevent flare-ups in people with ulcerative colitis (UC) who were already taking a standard medication. Out of 42 patients, 76% achieved therapeutic success after 12 months, but 95% of those taking the combination treatment improved significantly compared to just 57% of those on the standard medication alone. This is important because it shows that adding this new preparation can lead to better symptom control and quality of life for patients with UC. Who this helps: Patients with ulcerative colitis.

Plain English
This study looked at how genetic variations related to vitamin D might help predict if patients with Crohn's disease would achieve remission after treatment with a drug called adalimumab (ADA). Researchers followed 63 patients and found that specific genetic markers could be linked to remission rates at 3 and 12 months, with certain vitamin D-related genes showing significant influence. Understanding these connections could enhance how doctors select treatments for Crohn's disease and tailor them based on a patient's genetic makeup. Who this helps: This helps patients with Crohn's disease and their doctors in planning more effective treatment strategies.

Plain English
This study looked at the role of inflammatory bowel disease (IBD) nurses and how they can help patients with conditions like Crohn's disease and ulcerative colitis. It found that having an IBD nurse improves patient care by managing treatments, answering patient questions, and facilitating communication between doctors and patients. This teamwork not only helps patients manage their complex symptoms more effectively but also allows doctors to focus on more patients. Who this helps: This benefits patients with inflammatory bowel diseases and the healthcare teams that support them.

Plain English
This study looked at lung diseases that occur in patients with inflammatory bowel disease (IBD), specifically interstitial lung disease (ILD) and granulomatous lung disease (GLD). Researchers found that out of 31 patients with ILD, 64% developed the condition due to medication, and 80% had to go to the hospital; only 16% showed no respiratory symptoms at follow-up. For GLD, 36% were also linked to medication, with 45% requiring hospitalization. This matters because these lung diseases can significantly affect the quality of life for IBD patients, and monitoring drug side effects is crucial for better management. Who this helps: Patients with inflammatory bowel disease and their doctors.

Plain English
This research studied the effects of vedolizumab, a medication, on patients with chronic pouchitis, a complication tied to ulcerative colitis that doesn't respond well to standard treatments. Out of 44 patients treated, 75% saw clinical improvement after 12 weeks, and 74% showed improvement in their endoscopic evaluations within six months. This is important because it offers hope for effective treatment options for patients who have not responded to other therapies, like anti-TNF drugs. Who this helps: Patients with chronic refractory pouchitis.

Plain English
This study looked at eosinophilic colitis (EC), a rare disease where white blood cells called eosinophils build up in the colon, causing inflammation. The researchers found that diagnosing EC can be difficult because there are no clear guidelines for when eosinophil levels indicate this condition, and treatment options are mostly based on limited case studies rather than large, controlled research. Understanding and accurately diagnosing EC is important because it can lead to better treatment strategies for those affected. Who this helps: This helps patients suffering from eosinophilic colitis and their doctors.

Plain English
This study looked at how well a medication called ABP 501, a version of adalimumab, works for people with Crohn's disease. The findings showed that 60% of patients new to the treatment saw improvements in their condition within three months, and among those who switched from another version, 95% continued their treatment without issues after six months. This is important because it indicates that ABP 501 is effective and safe for managing Crohn's disease, offering patients a reliable alternative to the original drug. Who this helps: Patients with Crohn's disease.

Plain English
This study examined small bowel adenocarcinomas (SBAs) from patients with celiac disease, Crohn's disease, and those with no known cause. Researchers found that 26% of the SBAs had PD-L1 positivity, but this was much higher (35%) in tumors associated with celiac or Crohn's disease, compared to just 5% in sporadic cases. Also, SBAs with PD-L1 positivity showed better survival rates and more immune cell presence, suggesting they could respond well to immunotherapy treatments. Who this helps: Patients with small bowel adenocarcinomas, especially those with celiac disease or Crohn's disease.

Plain English
This study looked at a type of cancer called small bowel adenocarcinoma and found that the presence of a protein called PD-L1 is linked to the causes of the cancer and the immune cells that invade the tumor. Specifically, they found that patients with elevated PD-L1 levels often had certain genetic changes known as microsatellite instability. Understanding these links is important because it can help doctors identify which patients may respond better to immunotherapy treatments. Who this helps: This helps cancer patients and their doctors in deciding on more effective treatments.

Plain English
This study looked at how certain blood markers could predict how well patients with inflammatory bowel diseases (IBD) respond to biologic treatments. Researchers found that a decrease in a specific protein called interleukin-6 (IL-6) was linked to a better treatment response after 12 months; patients with a significant drop in IL-6 had nearly five times higher odds of doing well on the therapy. Understanding IL-6 levels helps doctors make more personalized treatment plans for patients with IBD. Who this helps: This benefits patients with inflammatory bowel diseases and their doctors.

Plain English
This study looked at proctitis, an inflammation of the anus and rectum, which can happen due to various infections, especially in people who engage in anal sex. The researchers found that infections like gonorrhea, chlamydia, herpes, and syphilis are commonly linked to proctitis, particularly in men who have sex with men, and emphasized that relying on specialists in infectious diseases is important for proper diagnosis and treatment. Understanding these connections helps improve treatment outcomes, as many cases can be effectively managed to prevent future issues. Who this helps: This benefits patients with proctitis, especially those at higher risk due to sexual practices.

Plain English
This study looked at the risk of bone fractures in patients with inflammatory bowel diseases (IBD) using a tool called the FRAX score. They found that the average risk of hip fractures over 10 years was 1.4%, while the risk of major fractures was 7.8%. Notably, patients with higher inflammation levels (indicated by a high erythrocyte sedimentation rate - ESR) had a significantly higher risk of fractures, with rates of 1.86% for hip fractures and 18% for major fractures compared to those with normal ESR levels. Who this helps: This research benefits patients with inflammatory bowel diseases and their doctors by highlighting the importance of monitoring inflammation to prevent fractures.

Plain English
This study looked at how two substances in the blood, interleukin-6 (IL-6) and interleukin-8 (IL-8), can predict how well patients with inflammatory bowel diseases will respond to a treatment called vedolizumab. The researchers found that if IL-8 levels dropped by more than 2.6 pg/mL in the first 10 weeks of treatment, there was a 66% chance that patients would have a positive response after 12 months. This is important because it helps doctors identify early who might benefit from vedolizumab, allowing for more personalized treatment plans. Who this helps: This helps patients with inflammatory bowel diseases and their doctors by guiding treatment decisions.

Plain English
This study explored the effects of Compositum Zeolite®, a mineral compound, on patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Among 14 patients who followed the treatment, those with Crohn's disease showed a significant improvement in their health scores from 5.3 down to 4 after eight weeks, and further down to 3.1 after 60 days, while ulcerative colitis patients did not show a significant change. These findings matter because they suggest that Compositum Zeolite® could be a helpful additional treatment for managing symptoms in Crohn's disease patients. Who this helps: Patients with inflammatory bowel disease, particularly those with Crohn's disease.

Plain English
This research studied whether people with inflammatory bowel disease (IBD) have a higher risk of developing prostate cancer compared to those without IBD. The analysis found that men with IBD have a 71% higher risk of prostate cancer, while the risks for those specifically diagnosed with Crohn's disease and ulcerative colitis were less pronounced at 10% and 22%, respectively. Understanding this connection is important because it can help guide screenings and healthcare for men with IBD. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at how inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, can cause changes in the mouth, with 5% to 50% of patients experiencing oral issues. It found that oral lesions may reflect the disease itself or be side effects of medications used to treat IBD. Fecal calprotectin, a simple stool test, can help identify which patients need further examination, reducing the need for more invasive procedures. Who this helps: This research benefits patients with IBD by improving diagnosis and treatment options for their oral health issues.

Plain English
This study looked at how a probiotic called ES1 affects patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Among 16 patients, those who took ES1 for 12 weeks showed significant improvements: 50% had positive results, abdominal pain improved in 62.5% of them, and inflammatory markers in their blood decreased. These findings suggest that ES1 can help reduce inflammation and improve symptoms in IBS-D patients, especially those treated for a longer duration. Who this helps: Patients suffering from diarrhea-predominant irritable bowel syndrome.

Plain English
This study looked at how well adding microencapsulated sodium butyrate (BLM) to standard treatment helps patients with ulcerative colitis (UC) stay in remission and reduce symptoms. Among 39 patients studied over 12 months, 64.1% achieved therapeutic success, with 83.3% of those receiving BLM seeing improvement, compared to only 47.6% in the standard treatment group. This research matters because it shows that sodium butyrate could be a helpful addition to existing treatments for patients with UC, leading to better management of their condition. Who this helps: Patients with ulcerative colitis seeking better control of their symptoms and remission.

Plain English
This study looked at a new treatment option for patients who couldn't get rid of a specific stomach infection after trying standard antibiotics. In a group of 302 patients, more than 72% were successfully treated using a combination of rifabutin, amoxicillin, and a stomach acid reducer over 14 days. This finding is important because it shows that rifabutin can be an effective and safe alternative for patients who have exhausted other treatment options. Who this helps: Patients with stubborn stomach infections that don't respond to standard treatments.

Plain English
This study looked at how well certain topical treatments work for healing inflammation in the rectal area of patients with perianal fistulizing Crohn's disease. The researchers found that mesalazine suppositories helped 50% of patients achieve and keep their rectal inflammation in remission, while other treatments like metronidazole and tacrolimus showed limited benefits. This matters because effective topical therapies could improve the quality of life for patients dealing with this painful condition. Who this helps: This helps patients with perianal fistulizing Crohn's disease.

Plain English
This study looked at how well a daily oral iron supplement called Feralgine® helped patients with inflammatory bowel disease (IBD) who also had anemia. After three months, patients saw their hemoglobin levels rise from an average of 11 g/dL to 12.2 g/dL, which is a significant increase, and 94% of patients managed to stick with the treatment despite some experiencing minor digestive issues. This is important because it shows that Feralgine® is an effective first-line treatment for managing anemia in IBD patients. Who this helps: This helps patients with inflammatory bowel disease who are dealing with anemia.

Plain English
This study looked at how effective it is to treat inflammatory bowel disease with two types of medications called biological therapies at the same time. Researchers found that 100% of the patients experienced clinical improvement after this treatment, with 93% showing improvements in their intestinal condition based on endoscopic evaluations. This matters because it highlights a potentially better treatment option for patients who don’t respond well enough to single therapies. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at whether genetic differences related to an enzyme called thiopurine S-methyltransferase (TPMT) affect how well patients with inflammatory bowel diseases (IBD) tolerate the medication azathioprine, which can cause side effects in some patients. Researchers reviewed data from 200 IBD patients and found that 60 had to stop azathioprine due to side effects, while 140 continued without issues. They discovered that only 4% had genetic mutations associated with TPMT, and those mutations did not significantly predict adverse effects from the drug. This finding means testing for these mutations before prescribing azathioprine isn't necessary, so patients who might benefit from the medication are not denied it. Who this helps: This helps IBD patients who need treatment options without the worry of genetic testing holding them back.

Plain English
This study looked at risk factors for spondyloarthritis, a type of arthritis that affects some patients with inflammatory bowel disease (IBD). Researchers surveyed 1,147 IBD patients and found that 21.3% had scores indicating a higher risk for spondyloarthritis. Key risk factors included being female, having Crohn's disease, and having been treated with immunosuppressant or biologic drugs. Who this helps: This information benefits doctors and healthcare providers who treat IBD patients, allowing them to identify those at risk for spondyloarthritis more effectively.

Plain English
This study looked at how the gut bacteria of patients with Crohn's disease changed after six months of treatment with a drug called adalimumab. They found that in patients who responded well to the therapy, a specific type of bacteria decreased significantly from 15.8% to 6.8%, while in those who didn't respond, the levels stayed the same. These findings suggest that successful treatment with adalimumab may help restore a healthier balance of gut bacteria, which is important for reducing inflammation and improving patient health. Who this helps: This helps patients with Crohn's disease and their doctors in managing the condition.

Plain English
This study looked at how well two different medications, adalimumab and azathioprine, stop bowel damage in people with Crohn's disease. Researchers found that 67% of patients taking adalimumab showed improvement after 12 months, while only 28.3% of those on azathioprine had similar results. This is important because it shows that adalimumab is more effective at preventing further damage in the intestines compared to azathioprine. Who this helps: Patients with Crohn's disease.